News | November 01, 2022
Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Plans to double its manufacturing footprint to bolster the growth
The product will be manufactured at Lupin's facility in Nagpur, India.
The companies will leverage their respective proprietary technology platforms
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Subscribe To Our Newsletter & Stay Updated
